- Johnson & Johnson is set to reveal promising data on TAR-200 at the 2025 American Urological Association Annual Meeting.
- Analysts predict an average stock price target of $170.64, with a potential upside of 8.81% from the current price.
- GuruFocus estimates reveal a potential 20.46% upside based on its GF Value calculation.
Johnson & Johnson (NYSE: JNJ) is poised to make headlines at the American Urological Association 2025 Annual Meeting with the anticipated release of new data. The focus will be on the promising TAR-200, a potential breakthrough as a standalone treatment for bladder cancer. This innovative study, known as SunRISe-1, examines the drug's efficacy as a chemotherapy delivery system in patients who have not responded to standard immunotherapy treatments.
Wall Street Analysts' Insights on Johnson & Johnson
According to projections from 24 experienced analysts, Johnson & Johnson's (JNJ, Financial) stock is expected to reach an average price target of $170.64 within a year. This includes a high estimate of $185.00 and a low estimate of $150.00, demonstrating a predicted upside potential of 8.81% from its current trading price of $156.83. For more in-depth analysis, visit the Johnson & Johnson (JNJ) Forecast page.
Brokerage Firm Recommendations
Johnson & Johnson's (JNJ, Financial) average brokerage recommendation stands at 2.3, indicating an "Outperform" status based on the consensus of 26 brokerage firms. This rating uses a scale from 1 to 5, where a score of 1 represents a Strong Buy, and 5 signifies a Sell. This consensus suggests optimism among analysts about the stock's future performance.
GuruFocus GF Value Analysis
Johnson & Johnson (JNJ, Financial) is projected to reach a GF Value of $188.92 within the next year, according to estimates by GuruFocus. This suggests a potential upside of 20.46% from its current price of $156.83. The GF Value represents an estimate of the stock's intrinsic value, determined by analyzing historical trading multiples, past business growth, and future performance projections. To explore detailed data, visit the Johnson & Johnson (JNJ) Summary page.
By staying informed and leveraging these insights, investors can make well-informed decisions about their portfolios, particularly regarding stocks with promising developments like Johnson & Johnson.
